A total of 280 patients at 8 centers were randomized. The patients were recruited into the trial prior to the coronary stenting procedure or after stent placement when fully recovered from sedation, at which time they gave informed consent. Prior to stent implantation patients received aspirin at a dose of 100-200 mg/day and a loading dose of clopidogrel of at least 300 mg (up to 600 mg), as per routine care. After obtaining informed consent and after the procedure, if a stent was placed successfully without in-laboratory complications, aspirin, clopidogrel, and cilostazol were continued for 1 month. From the 2 nd month, the patients were randomized to aspirin (100-200 mg/day) and cilostazol (200 mg/day) vs aspirin (100-200 mg/day) and clopidogrel (75 mg/day). Study drugs were continued for 6 months. The patients were also randomized for the type of DES: Cypher vs Taxus stents. All other medications were continued. Cardiac enzymes (ie, creatine kinase (CK), CK-MB, troponin I) were measured at 8-12 h after the procedure and repeated 8 h later if more than twice the upper normal limit (UNL). Myocardial infarction (MI) was diagnosed as a 3-fold elevation of the UNL. Inclusion criteria were: (1) target lesion either de novo or restenosis lesion >50% and <100% diameter stenosis (DS) by visual estimate, (2) successful, uncomplicated DES placement with <10% residual stenosis by visual estimate, with Thrombolysis In Myocardial Infarction III flow, without dissection, (3) stented segment <40 mm by visual estimate, (4) age >18 years, (5) negative pregnancy test in women of child bearing potential and commitment to use contraception or abstinence for the duration of the study, (6) able to give informed consent, (7) able to return for follow-up angiography at 6 months, and (8) non-insulin dependent DM. Exclusion criteria included: (1) prior PCI within 6 months, (2) thrombocytopenia defined as platelet level <150,000/ml, (3) known bleeding diathesis, (4) known intolerance to cilostazol, aspirin or clopidogrel, (5) acute MI with CK elevation 3-fold higher than the UNL within 24 h, (6) intraluminal thrombus at target lesion, (7) moderate to severe target lesion calcification, (8) target lesion encompassing side branches >2 mm in diameter, (9) heart failure or ejection fraction <30%, (10) active peptic ulcer disease or gastrointestinal bleeding, (11) renal insufficiency with creatinine >2.5 mg/dl, (12) need for warfarin anticoagulation, (13) known hepatic dysfunction, (14) current participation in another randomized trial, (15) inability to return for follow-up angiography, (16) major life-threatening illness, and (17) taking cilostazol within 6 months.
Coronary Angiography and Follow-up
Patients were followed up clinically at 1, 3, and 6 months after stenting and at 6 months they had follow-up angiography. The occurrence of adverse reactions was prospectively monitored. The window for follow-up angiography was 6-9 months. Patients who had early angiography with ISR (>50% DS) and/or target lesion revascularization (TLR) prior to the 4-month window was considered to have reached the endpoint and did not undergo additional angiography. Patients with early angiography, but without ISR or TLR, required additional angiography within the window. Images with optimum delineation of the target lesion were selected from among all technically suitable angiograms, and quantitative coronary angiography (QCA) was performed in the core laboratory (Gachon Gill Heart Center) by 2 physicians without any knowledge of the patient's clinical history. The measurements were calibrated using a guide catheter for reference. The reference diameter, minimum luminal diameter (MLD), percent diameter stenosis (%DS), acute gain, and late loss were determined. The acute gain was calculated from the difference between the MLD values before and after stenting. The late loss was calculated as the difference between MLD after stent implantation and the MLD at follow-up, and the loss index was defined as the late loss/acute gain ratio.
Endpoints
The primary endpoints were MLD at 6 months of the first lesion stented per patient, as assessed by QCA. The secondary endpoints were mean %DS per stented segment and binary restenosis, defined as >50%DS per stented segment, and major adverse cardiac events.
Statistical Analysis
Continuous variables are shown as mean ± standard deviation and categorical variables as proportions. Continuous variables were compared by unpaired t-test or analysis of variance as appropriate. Categorical variables were compared by chi-square. All data was analyzed by intention-to-treat. A p value <0.05 was considered to be significant.
Results

Baseline Patient Characteristics
A total of 280 patients were randomly assigned to either cilostazol (141: group I) or clopidogrel (139: group II) after successful stent implantation between January 2004 and February 2006. The baseline patient characteristics did not significantly differ between the groups, including age, sex, clinical diagnosis, risk factors etc (Table 1) .
Baseline Angiographic Characteristics, Stent Type, and Stent Implantation Procedure Characteristics
There were no significant differences between the groups in the angiographic characteristics ( Table 2 ). The lesion types at the stent placement site did not significantly differ, nor was there a significant difference in the type of the stent 
MLD, minimal luminal diameter; F-U, follow-up.
implanted or the stent implantation procedure characteristics (Table 3 ). All patients received unfractionated or lowmolecular-weight heparin.
QCA QCA analysis at the time of stent implantation showed no significant differences in reference diameter, MLD before or immediately after procedure, or lesion length (Table 4) . Follow-up coronary angiography was performed in 237 patients [113 patients in the cilostazol group (80.1%); 124 patients in the clopidogrel group (89.2%)]. Mean follow-up duration was 7.1±2.4 months. On follow-up QCA, the MLD at the stent implantation site (stent plus 5-mm borders) did not significantly differ between the cilostazol group (2.55± 0.63 mm) and the clopidogrel group (2.41±0.83 mm) (p= NS). Restenosis occurred in 9 patients from the cilostazol group (8.0%) and 20 patients from the clopidogrel group (16.1%) (p=0.041). There was no significant difference in the late loss of the cilostazol group (0.22±0.48 mm) and that of the clopidogrel group (0.26±0.78 mm) (p=NS) ( Table 5 ). Acute and subacute stent thrombosis within 1 month did not occur in either group. Cases of late stent thrombosis were 1 (0.9%) in group I and 1 (0.8%) in group II.
Clinical Evaluation
All patients were monitored until follow-up angiography, and all deaths, non-fatal cardiovascular events, and other non-fatal adverse events were investigated. There was 1 death in the cilostazol group. Acute MI did not occur in either group. TLR was performed in 7 cases (5.0%) in the cilostazol group and in 15 (10.8%) in the clopidogrel group.
Because glycemic control could have influenced the restenosis rate, we analyzed the level of hemoglobin (Hb) A1c in both groups. The baseline level of HbA1c in the clopidogrel group was 7.7±1.3% and 7.6±1.5% in the cilostazol group. At follow-up, the level of HbA1c in the clopidogrel group was 7.8±2.2% and 7.8±2.3% in the cilostazol group. No significant differences were observed in either group in the initial or follow-up period.
Adverse Reactions
Significant adverse reactions were not reported in either group.
Discussion
This randomized, open-labeled trial demonstrated that the effect of combination therapy with aspirin and cilostazol on ISR in high-risk patients with DM who underwent DES implantation was comparable to that of aspirin and clopidogrel therapy group. There was significantly less binary restenosis in cilostazol-treated patients compared with clopidogrel-treated patients (8.0% vs 16.1%).
The CREST trial 6 (in which patients received, in addition to aspirin, cilostazol 100 mg b.i.d. or placebo for 6 months; clopidogrel 75 mg daily was administered to all patients for 30 days) demonstrated that treatment with cilostazol resulted in a significantly larger MLD and a significantly lower binary restenosis rate compared with placebo-treated patients after bare-metal stent implantation. The reduction in restenosis observed in this trial was greater than that observed in the pivotal STRESS 7 and BENESTENT trials. 8 Before the DES era, recognized predictors of increased restenosis included DM, small vessel diameter, lesion length, and left anterior descending coronary artery site, chronic total occlusion etc. 6 Cilostazol proved to be effective in reducing the rate of restenosis in non-diabetics, and its use in oral agent-treated diabetics was associated with a highly significant 63% reduction in restenosis. 6 Although DES has reduced the incidence of post-procedural restenosis, adjunct pharmacologic therapy to prevent ISR may be desirable, particularly in patients at high-risk for restenosis, such as those with DM, long lesions, and small vessels.
Patients with DM who have severe endothelial damage often undergo angioplasty. The results of in vivo experiments have shown significant benefits with the use of cilostazol. Aoki et al 9 designed a study using a ballooninjury rat model to determine the effects of cilostazol on neointimal formation in diabetic and nondiabetic animals. They found a significant reduction in the ratio of neointimal to medial area, even in the diabetic rats.
The mechanism of cilostazol treatment in the improvement of restenosis can be explained as follows. 10 Cilostazol decreases the activity of phosphodiesterase type 3, leading to accumulation of cAMP, which initiates a cascade of events including upregulation of the anti-oncogenes p53 and p21 and upregulation of hepatocyte growth factor (HGF). The increase in p53 protein blocks cell cycle progression and induces apoptosis in vascular smooth muscle cells (VSMC), leading to an antiproliferative effect. Upregulation of local HGF stimulates rapid regeneration of endothelial cells, which inhibits neointimal formation via 2 mechanisms: inhibition of abnormal VSMC growth and improvement of endothelial function.
Recent reports have demonstrated that the risk of stent thrombosis is similar between DES and bare-metal stents, 11 but there are 2 important issues regarding DES. In the ACC/AHA/SCAI and ESC guidelines long duration of clopidogrel treatment is recommended, especially in highrisk patients such as those with DM 12,13 and a considerable rate of aspirin and clopidogrel resistance is present. 14 Therefore, a different mechanism or stronger antiplatelet agents will be needed in some patients. In the present study, aspirin, clopidogrel, and cilostazol were continued for 1 month and 1 case of late stent thrombosis occurred in each group. Previous studies demonstrated that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting and has an additive effect. 15, 16 
Study Limitations
First, aspirin, clopidogrel, and cilostazol were continued for 1 month in both groups before randomization and such a triple antiplatelet regimen could affect the pure outcomes of both groups. Second, even though this was a randomized study, the number of patients and the follow-up rate of coronary angiography was not sufficiently high enough to reach a clear conclusion. Third, intravascular ultrasound study (IVUS) was not used for the precise analysis of the extent of plaque burden and neointimal area at the stent site. At present, we are planning to analyze the stent site in both groups by IVUS.
Conclusion
The pleotropic effects of cilostazol, in addition to its antithrombotic and vasodilatory attributes, make it a potentially viable treatment option for preventing restenosis following coronary stenting, especially in patients with DM. Our results demonstrated that the effects of combination therapy with aspirin and cilostazol for the prevention of stent thrombosis and restenosis were comparable or superior to those of aspirin and clopidogrel.
